Responsiveness of the activated partial thromboplastin time and dilute thrombin time to argatroban: Results of an in vitro study

2020 ◽  
Vol 42 (3) ◽  
Author(s):  
Erica Scalambrino ◽  
Lidia Padovan ◽  
Veena Chantarangkul ◽  
Marigrazia Clerici ◽  
Andrea Artoni ◽  
...  
Keyword(s):  
Partial Thromboplastin Time ◽  
In Vitro Study ◽  
Activated Partial Thromboplastin Time ◽  
Vitro Study ◽  
Thrombin Time

scholarly journals The In Vitro Effects of Pentamidine Isethionate on Coagulation and Fibrinolysis

Molecules ◽  
2019 ◽  
Vol 24 (11) ◽  
pp. 2146 ◽  
Author(s):  
Rami A. Al-Horani ◽  
Daytriona Clemons ◽  
Madhusoodanan Mottamal
Keyword(s):  
Partial Thromboplastin Time ◽  
Factor Xa ◽  
Activated Partial Thromboplastin Time ◽  
Factor Xiiia ◽  
Thrombin Time ◽  
Normal Plasma ◽  
Pentamidine Isethionate ◽  
In Vitro Effects ◽  
Coagulation And Fibrinolysis

Pentamidine is bis-oxybenzamidine-based antiprotozoal drug. The parenteral use of pentamidine appears to affect the processes of blood coagulation and/or fibrinolysis resulting in rare but potentially life-threatening blood clot formation. Pentamidine was also found to cause disseminated intravascular coagulation syndrome. To investigate the potential underlying molecular mechanism(s) of pentamidine’s effects on coagulation and fibrinolysis, we studied its effects on clotting times in normal and deficient human plasmas. Using normal plasma, pentamidine isethionate doubled the activated partial thromboplastin time at 27.5 µM, doubled the prothrombin time at 45.7 µM, and weakly doubled the thrombin time at 158.17 µM. Using plasmas deficient of factors VIIa, IXa, XIa, or XIIa, the concentrations to double the activated partial thromboplastin time were similar to that obtained using normal plasma. Pentamidine also inhibited plasmin-mediated clot lysis with half-maximal inhibitory concentration (IC50) value of ~3.6 μM. Chromogenic substrate hydrolysis assays indicated that pentamidine inhibits factor Xa and plasmin with IC50 values of 10.4 µM and 8.4 µM, respectively. Interestingly, it did not significantly inhibit thrombin, factor XIa, factor XIIIa, neutrophil elastase, or chymotrypsin at the highest concentrations tested. Michaelis-Menten kinetics and molecular modeling studies revealed that pentamidine inhibits factor Xa and plasmin in a competitive fashion. Overall, this study provides quantitative mechanistic insights into the in vitro effects of pentamidine isethionate on coagulation and fibrinolysis via the disruption of the proteolytic activity of factor Xa and plasmin.

Copolymers of 2-acryloylamido-2-methylpropanesulfonic acid and acrylic acid with anticoagulant activity

e-Polymers ◽  
2003 ◽  
Vol 3 (1) ◽  
Author(s):  
Dilyana Paneva ◽  
Olya Stoilova ◽  
Nevena Manolova ◽  
Dobri Danchev ◽  
Zdravko Lazarov ◽  
...  
Keyword(s):  
Acrylic Acid ◽  
Prothrombin Time ◽  
Partial Thromboplastin Time ◽  
Anticoagulant Activity ◽  
Activated Partial Thromboplastin Time ◽  
Thrombin Time

Abstract Copolymers of 2-acryloylamido-2-methylpropanesulfonic acid (AMPS) and acrylic acid (AA), as well as the corresponding homopolymers PAMPS and PAA, were studied in vitro on human pool plasma for their anticoagulant activity. The values of the haemostatic parameters - prothrombin time, activated partial thromboplastin time and thrombin time - depend on the composition and the concentration of the (co)polymers. Reptilase time remains unchanged on adding the (co)polymers. A broad concentration range from 16 μg/ml to 3 mg/ml was studied. The copolymers possess anticoagulant activity, which is higher at higher content of AMPS units. It was found that, at certain concentrations, the haemostatic parameters of PAMPS are close to that of heparin. PAA has the lowest anticoagulant activity.

scholarly journals Evaluation of Hemocompatibility of Titanium after Various Surface Treatments: An in vitro Study

2012 ◽  
Vol 2 (4) ◽  
pp. 136-142
Author(s):  
Yemineni BhavanChand ◽  
R Ranzani ◽  
H Annapoorani
Keyword(s):  
In Vitro Study ◽  
Surface Treatments ◽  
Vitro Study ◽  
Polished Surface ◽  
Thrombin Time ◽  
Before And After ◽  
Phosphate Buffered Saline ◽  
Mechanical Surface ◽  
Medical Grade

ABSTRACT Objective To evaluate the hemocompatibility of titanium after various surface treatments. Materials and methods A total of 27 disk-shaped specimens (3 ⨯ 10.0 mm) were prepared from a cylindrical rod of medical grade titanium. The disks were divided into three groups, of which one was considered as the control (mechanical surface polished surface). The other groups being sandblasted disks and anodized disks. Surface evaluation was done for sandblasted and anodized disks with scanning electron microscope. The specimens were placed in polystyrene culture plates and agitated with phosphate buffered saline for 5 minutes before they were exposed to blood taken from human volunteer. The materials were under 30 minutes agitation at 75 ± 5 rpm using an Environ shaker thermostated at 35 ± 20°C. The total hemoglobin from the initial sample was measured using automatic hematology analyzer. Percentage hemolysis, thrombin time, platelet adhesion and activation were assessed. Significant differences between different treated titanium materials were determined using Minitab® Version 15.1.1.0. A two-sample t-test was performed to find the p-values for different groups of data. Results After 30 minutes of agitation, cells began to spread on the test surfaces. There was a clear reduction in the number of platelets before and after exposure to titanium samples. Reduction of leukocytes was seen to a least extent on the anodized surface. Rough surface induced higher hemolysis than other groups. Platelet reduction and leukocyte reduction in all the three surfaces was quite higher than that obtained for reference plate. Surface variation has no significance on the thrombogenic capabilities of medical grade titanium (p < 0.05). Significance The hemocompatibility of medical grade titanium did not vary with different surface modifications. How to cite this article BhavanChand Y, Ranzani R, Annapoorani H. Evaluation of Hemocompatibility of Titanium after Various Surface Treatments: An in vitro Study. Int J Prosthodont Restor Dent 2012;2(4):136-142.

Sign in / Sign up

Export Citation Format

Share Document